Table 1 Characteristics of the included studies.
Studies | Country | Study period | Mean age (range, years) | Female (%) | Median f/u (range, months) | WHO classification | bGTR | Inclusion | Number of patients |
|---|---|---|---|---|---|---|---|---|---|
GTR + PORT vs. GTR | |||||||||
aKim 200312 | Korea | 1982–1999 | 41 (18–64) | 29 | 81 (7–216) | NA | I,II | HPC | 5 vs. 17 |
Schiariti 201121 | UK | 1984–2008 | 44.1 (19–80) | 49 | 123 (2–384) | NA | I,II | HPC | 3 vs. 10 |
Rutkowski 201222 | USA | 1989–2010 | 48 (18–71) | 57 | NA (2–408) | NA | NA | HPC | 9 vs. 7 |
Ghia 201323 | USA | 1979–2009 | 41 (0.1–71) | NA | NA | NA | MRI | HPC | 16 vs. 15 |
aMenon 201510 | India | 2000–2013 | 38.1 (13–67) | 47.6 | Mean 4.6 years (2–11 years) | NA | I,II | HPC | 10 vs. 3 |
Champeaux 201724 | UK | 2000–2016 | 51.3 | 42 | 7.8 years (IQR, 2.6–11.6 years) | 2000,2007,2016 | NA | SFT and HPC | 15 vs. 17 |
Zhang 201717 | China | 2008–2016 | 42 (7–73) | 50 | 46.9 (IQR, 47.4) | 2007 | NA | HPC | 47 vs. 39 |
aChampeaux 201825 | France | 1997–2016 | 49.9 | 82 | 7.8 years (IQR, 3.8–11.3 years) | 2000,2007,2016 | I–III | SFT and HPC | 6 vs. 5 |
aGubian 201911 | Germany | 2006–2015 | 45.3 (34–60) | 28 | 37.7 (6–108) | 2016 | NA | SFT and HPC | 14 vs. 8 |
aShin 202126 | Korea | 1995–2019 | 44 (15–70) | 46 | 77.9 (0.8–224.8) | 2016 | I,II | SFT/HPC | 37 vs. 23 |
aLee 202216 | Korea | 1995–2016 | 43 (12–74) | 50 | 76.9 | 2016 | NA | SFT/HPC | 54 vs. 32 |
aLi 202227 | China | 2008–2021 | 53 (25–75) | 61 | 82.7 (12–158) | 2021 | I,II | SFT | 9 vs. 18 |
